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a  b  s  t  r  a  c  t
Regional  differences  in human  papillomavirus  (HPV)  genotypes  and  the  presence  of mixed  HPV  infec-
tions  may  affect  adversely  the  efﬁcacy  of the HPV  vaccine.  Therefore,  a simple  and  high-throughput  HPV
genotyping  system  is required.  Recently,  a novel  HPV  genotyping  kit  (the  MebgenTM HPV  kit)  was  devel-
oped.  This  kit  uses  multiplex  PCR and  Luminex  xMAPTM technology  to detect  13  types  of high-risk  HPVs
and  an internal  control  in  a 96-well  format.  In the  present  study,  the  analytical  performance  of  the  kit
was  examined  using  HPV  plasmid  DNA.  All  13  types  of  HPVs  were  detected  with  a minimum  detection
sensitivity  of  250  copies/test,  and  highly  speciﬁc  signals  were  observed.  HPV  16  plasmid  was  detected
in  samples  containing  mixtures  with  other HPV-type  plasmids  in  ratios ranging  from  1:1  to  1:1000.  No
cross  reactivity  was  observed  with  DNA  from  27  types  of other  infectious  microbes.  A  clinical  evaluation
was  carried  out  using  cervical  samples  from  356  patients  with  persistent  abnormal  smears  diagnosed  at
mass  public  health  screenings  for cervical  cancer.  The  samples  were  preserved  in  TacasTM medium  until
analysis.  HPV  was  detected  in  162  (45.5%)  samples  including  110  (67.9%)  with  single  infections  and  52
(32.1%)  with  multiple  infections.  The  type  distribution  of  the  13  high-risk  HPVs  was  as follows:  28.4%
HPV  16,  11.7%  HPV  18,  6.8%  HPV  31,  3.1%  HPV  33,  3.7%  HPV  35, 9.3%  HPV  39,  1.9% HPV  45,  8.6%  HPV  51,
37.0%  HPV  52, 9.3%  HPV  56, 16.7%  HPV  58,  3.7%  HPV  59, and  1.9%  HPV  68.  To  evaluate  sample  stability
over  time,  changes  in the  detection  of  HPV  DNA  derived  from  HeLa  and  SiHa  cells  were  measured  in
3  types  of liquid-based  cytology  media.  HPV  DNA  was  detected  in  Tacas  and  ThinprepTM samples  after
storage  at  4 ◦C  or 30 ◦C for 4 weeks  and  within  1 week  of  collection  in  SurepathTM samples.  These  results
suggest  that  this  newly  developed  HPV  genotyping  kit  is  suitable  for use  in  both  clinical  applications  and
large-scale  epidemiological  studies.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).Abbreviations: HPV, human papillomavirus; PCR, polymerase chain reaction;
NA, deoxyrbonucleic acid.
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20-0942, Japan. Tel.: +81 76 265 2608; fax: +81 76 234 4369.
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166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article u1. Introduction
In many countries, the Papanicolaou-stained (Pap) cytological
smear has been used conventionally for detecting cervical cancer
precursor lesions, and its use has reduced successfully the incidence
of cervical cancer. However, a limitation of this test is its relatively
low sensitivity of 50% (Baldwin et al., 2003; Michalas, 2000; Wright,
2007). The development of cervical cancer is known to be associ-
ated with human papillomavirus (HPV) infection (Burd, 2003; zur
Hausen, 2002). More than 100 types of HPV have been identiﬁed
from differences in the DNA sequence of the L1 open reading frame,
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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nd approximately 40 types of HPV have been reported to infect the
enital tract (Bosch et al., 2002; Munoz et al., 2003). Twelve high-
isk HPV types have a causal link with cervical cancer (Bouvard et al.,
009), in particular, HPV 16 and HPV 18 are associated strongly
ith a higher risk for the progression of cervical cancer (Kjaer et al.,
010).
Recently, HPV DNA tests have been developed for early can-
er screening using molecular biology techniques, and these can
dentify women at increased risk of developing cervical cancer. In
009, the American society for colposcopy and cervical pathology
mplemented clinical guidelines for individualized examinations
hat focused on the combination of an HPV DNA test and a Pap test
n cervical cancer screening. In 2012, these guidelines were updated
o improve the management of abnormal screening tests, including
iscordant HPV and Pap co-testing results, by deﬁning when rou-
ine screening is required after initial assessment and expanding
he management guidelines for adolescents to include women up
o the age of 25 years. In 2010, the Japanese government approved
he use of the HPV DNA test as a triage test for patients with “atyp-
cal squamous cells of undetermined signiﬁcance”, and in 2012,
PV genotyping was approved for women diagnosed with cervical
ntraepithelial neoplasia grade 1 or 2 on colposcopic biopsy.
In a recent study of a Columbian population screened using an
PV genotyping test, the multiple infection rate was found to be
igher and the disease more advanced (Ili et al., 2011). HPV geno-
yping appears to be suitable highly for large-scale epidemiological
nd vaccination studies as well as for diagnostic screening and
etermining clinical treatment strategies (Castle et al., 2009; Chen
t al., 2011). Furthermore, HPV genotyping is valuable for investi-
ating the epidemiology of HPV and for monitoring the efﬁciency
f HPV vaccination trials (Schmitt et al., 2006).
The current US food and drug administration-approved Hybrid
aptureTM 2 (HC2) test (Qiagen, Gaithersburg, MD,  USA) lacks the
bility to speciﬁcally genotype HPV and only determines samples
s positive for high-risk HPV types. The MebgenTM HPV kit (MBL,
agoya, Japan) has been listed in the national health insurance
eport as a newly commercialized HPV genotyping method. This
it is able to detect 13 types of high-risk HPVs (16, 18, 31, 33,
5, 39, 45, 51, 52, 56, 58, 59, and 68). It uses the PCR-reverse
equence-speciﬁc oligonucleotide probe (PCR-rSSO) method with
uminex xMAPTM (Luminex, Austin, TX, USA) technology in a 96-
ell format and incorporates human -globin genes as an internal
ontrol. With this method, the HPV DNA and -globin genes in
pecimens are ampliﬁed by type-speciﬁc primers used for multi-
lex PCR. Subsequently, PCR products are detected by synthetic
ligonucleotide probes with complementary sequences. Luminex
s a high-throughput assay system that uses ﬂow cytometry and
ead sets coupled to probes that recognize and bind PCR products.
ach bead set is characterized by a discrete spectral reference given
y the combination of red and infrared ﬂuorophores within the
pheres. The target DNA is tagged ﬂuorescently with streptavidin
abeled with R-phycoerythrin (SAPE), and the beads are analyzed
ndividually with a red laser that recognizes the bead set and a
reen laser that provides a quantitative readout of the bound tar-
et (Dunbar et al., 2003). To evaluate the analytical performance of
his newly developed HPV genotyping kit, HPV plasmid DNA and
linical samples were examined under several conditions.
. Materials and methods
.1. Control plasmid DNARecombinant plasmid DNA was prepared for use as a positive
ontrol to determine the analytical sensitivity and speciﬁcity of the
PV genotyping kit. The plasmid DNA was prepared by insertingl Methods 204 (2014) 73–80
the synthesized L1 and L2 regions of each HPV genotype into
pIDTBluev2 (IDT) vectors, and the concentration was  adjusted to
50 copies/l with TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 8.0)
and mixed with 2 ng/l human genomic DNA. Human genomic
DNA at a concentration of 2 ng/l in TE buffer was  used as an HPV
negative control. The L1 and L2 regions of the 13 high-risk HPV
types were synthesized on the basis of the DNA sequences obtained
from Genbank [accession nos.: HPV 16 (K02718), HPV 18 (X05015),
HPV31 (J04353), HPV 33 (M12732), HPV 35 (M74117), HPV39
(M62849), HPV 45 (X74479), HPV 51 (M62877), HPV 52 (X74481),
HPV 56 (X74483), HPV 58 (D90400), HPV 59 (X77858), and HPV
68 (M73258)]. All plasmid DNA constructs were conﬁrmed by
PCR-ampliﬁed DNA sequencing.
2.2. Clinical samples
All 356 samples were obtained from patients (mean age, 40.4
years; median, 38.5 years; range, 20–85 years) with persistent
abnormal smears diagnosed during public health screening for cer-
vical cancer at Kanazawa University Hospital (Ishikawa, Japan) and
Toho University Hospital (Tokyo, Japan). Samples were collected
using the Cervex-brushTM combi (Rovers Medical Devices, Oss, The
Netherlands) and were stored in TacasTM gyn preservative solution
(MBL, Tokyo, Japan) at 4 ◦C for 1 month. The collection of all cer-
vical samples was  approved by and conducted in accordance with
the human research ethics committee of each hospital.
2.3. Mebgen HPV assay
2.3.1. DNA extraction
DNA was extracted from 1.0 ml  of each sample using the Smi  test
EX-R&D DNA extraction kit (MBL) according to the manufacturer’s
instructions. Template DNA was stored at −20 ◦C until use.
2.3.2. Multiplex PCR
Extracted DNA was  ampliﬁed using multiplex PCR with a set of
14 primers recognizing HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68 and -globin (Table 1). The ampliﬁcation was
performed in 96-well plates (Thermo fast 96 PCR plate; Thermo
Fisher Scientiﬁc, Yokohama, Japan) in a ﬁnal volume of 25 l [20 l
master mix, including primers, Taq DNA polymerase, and Uracil-
DNA-glycosylase (UDG), and 5 l extracted DNA]. Reactions were
heated for 5 min  at 40 ◦C and 2 min at 95 ◦C, followed by 35 repeat-
ing cycles of 94 ◦C for 30 s, 61 ◦C for 60 s, 72 ◦C for 30 s, and 72 ◦C
for 7 min  before a ﬁnal extension step at 94 ◦C for 10 min. PCR was
performed in the Gold 96-well gene amp  PCR system 9700 (Applied
Biosystems, Foster City, CA, USA).
2.3.3. Hybridization and ﬂuorescent labeling
Following the PCR ampliﬁcation, 5 l of PCR products and 25 l
of hybridization solution containing 15 types of probe (Table 1)-
coupled beads of each set were transferred to 96-well plates
(Thermo fast 96 plate non-skirted low proﬁle; Thermo Fisher Sci-
entiﬁc). Hybridization was performed at 95 ◦C for 2 min  followed
by 50 ◦C for 25 min  using the Gold 96-well gene amp  PCR sys-
tem 9700. After hybridization, wash buffer was  added to each well,
and the plates were centrifuged at 2000 g for 1 min. Subsequently,
supernatants were removed. After further washing steps, the beads
were resuspended in 50 l of R-phycoerythrin solution at 50 ◦C for
15 min.
2.3.4. Fluorescence measurement
The beads were analyzed for internal bead color and R-
phycoerythrin reporter ﬂuorescence on the Luminex 100/200. The
median reporter ﬂuorescence intensity (MFI) of at least 50 beads
was computed for each bead set in the sample. The cut-off value for
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Table  1
Oligonucleotide primers and probes for multiplex PCR using the Mebgen HPV kit.
HPV type Region Primer sequence (5′ → 3′) Amplimer
length (bp)
Probe sequence (5′ → 3′)
HPV
16
L1
Forward GATACTACACGCAGTACAAATATGTC
98 TTCTGAAGTAGATATGGCAGCACReverse CCATGTCGTAGGTACTCCTTAAAG
HPV
18
L1
Forward CGCAGTACCAATTTAACAATATGTGC
108 TTTGGTAGCATCATATTGCCCAGGReverse CAAATCATATTCCTCAACATGTCTGC
HPV
31
L1
Forward TACCACACGTAGTACCAATATGTCTG
104 TGCTGCAATTGCAAACAGTGATACReverse ATTCCTCACCATGTCTTAAATACTCTT
HPV
33
L1
Forward GGATACCTATAGGTTTGTTACCTCT
90 TTTGACACGTAATAGCCTGAGAGReverse GTATATTTACCTAAGGGGTCTTCCT
HPV
35
L1
Forward CACATATCGCTATGTAACATCACAGG
76 ACTTGTCAAAAACCCAGTGCACReverse TAATGGATCATCTTTAGGTTTTGGTG
HPV
39
L1
Forward CTGCCAGTTTGGTAGACACTTAC
142
AACTTTAGACCGTCATATGGAT
Reverse TCCAAACTAAACTTTTCCCTTAAGTC TATGACGGTCTAAAGTTTTGGAAa
HPV
45
L1
Forward CGTTTTGTGCAATCAGTTGCTG
117 ATATGGATCCTGCTTTTCTGGReverse GGAGGAAAATTTTTCCTTTAGGTCA
HPV
51
L1
Forward CCTGTGTTGATACTACCAGAAGTAC
90 AGCAGTGGCAGTGCTAATAGTReverse GCTTAAAGTTACTTGGAGTAAATGT
HPV
52
L2
Forward AGGTTTGGGTATAGGTACAGGTG
95 GCACATAGCCTGCCCTACCAReverse TGGACGTGGTAATACTACTAGTGG
HPV
56
L1
Forward GGGGTAATCAATTATTTGTTACTGTAG
118 GTACTGCTACAGAACAGTTAAGTAReverse CTAAGGTACTGATTAATTTTTCGTGC
HPV
58
L1
Forward GGACACATATAGATTTGTTACCTCC
115 GGTGCTGTTTTTTGGCAAGTAReverse TTCCTTTAAGTTAACCTCCCAAAAAG
HPV
59
L1
Forward GCTAGTTTAGTTGACACATACCGT
104 CTGTTTAACTGGCGGTGCGGReverse AACTTTAGTTTGTCATAAGGGTCCT
HPV
68
L1
Forward TGTTGTGGATACCACTCGCAGT
114 CAGCTGATTCAGTAGTAGTAGACReverse TCCTCAACATGCCTAATATATTCC
Forward CAACTTCATCCACGTTCACC
AGGT
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Globin Reverse GAAGAGCCAAGGAC
a Two types of probes were conferred in HPV 39.
 positive result was set at three times the MFI  value of the negative
ontrol. HPV genotypes were generated automatically using the
PonentTM software (Luminex) that recognizes ﬂuorescent peaks
ccording to speciﬁc color and size.
.4. Cloning and sequencing
To evaluate the genotypic speciﬁcity of the kit, 52 samples com-
rising 4 samples of each of the 13 types of HPV were selected
andomly from 132 HPV-positive samples among the 356 clinical
amples. This approach eliminated concerns about multiple HPV
nfection in this cloning and sequencing procedure. One HPV type-
peciﬁc primer was used per sample of DNA. The PCR products were
xtracted using SuprecTM-EZ (Takara Bio, Otsu, Japan) and cloned
irectly into pCR2.1 Topo TA cloningTM vector (Invitrogen, Carlsbad,
A, USA) according to the manufacturer’s instructions. The cloned
lasmids were sequenced with an ABI PrismTM 3100 genetic ana-
yzer (Applied Biosystems). HPV-DNA types were conﬁrmed using
he basic local alignment search tool (BLAST) database on the NCBI
ebsite (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
.5. Sample stability study
To examine the inﬂuence of sample storage conditions on HPV
enotyping, changes in MFI  over time were measured in 3 types of
iquid-based cytology media. HeLa cells (containing HPV 18) and
iHa cells (containing HPV 16) were obtained from the American
ype Culture Collection (Manassas, VA, USA) and were maintained
n Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
etal bovine serum. Each cell type was maintained in a vial of268 CTAGGGTGTGGCTCCACAGGAC
liquid-based cytology media at a concentration of 1 × 105 cells/ml.
To determine the optimal preservation period, DNA was extracted
after preservation for 1–4 weeks at 4 ◦C or 30 ◦C. The liquid-based
cytology media used were as follows: the Tacas medium as an
example of an ethanol-based ﬁxative, the ThinprepTM medium
(Hologic, Bedford, MA,  USA) as an example of a methanol-based
ﬁxative, and the SurepathTM medium (BD, Franklin Lakes, NJ, USA)
as an example of an ethanol-based ﬁxative including formaldehyde.
3. Results
3.1. Analytical performance
The speciﬁcity of the bead-coupled oligonucleotide probes was
determined by hybridizing control plasmid DNA  obtained from all
13 HPV genotypes and -globin to a bead mixture comprising all
speciﬁc probes. All samples were tested in 3 separate assays. Highly
speciﬁc signals were observed for all 13 HPV type-speciﬁc probes
with the respective control plasmid DNA (Table 2).
The cut-off value of MFI  was calculated from the measurement
data of 756 samples (three lots of 13 control plasmid DNA samples
and human genomic DNA solutions were measured 18 times). The
largest sample value of 10 standard deviations above the average
negative sample value was 1382 for the HPV 39 bead, followed by
682 for the HPV 58 bead. The largest maximum sample value was
363 for the HPV 59 bead, followed by 758 for the HPV 39 bead. The
smallest minimum sample value of 3 standard deviations below the
average positive sample value was  1600 for the HPV 68 bead, fol-
lowed by 5041 for the HPV 39 bead. The smallest minimum sample
value was  2792 for the HPV 68 bead, followed by 5574 for the HPV
76
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Table 2
Speciﬁcity and reproducibility of multiplex PCR products using control plasmids.
Plasmid Beads Median ﬂuorescence intensity (MFI)
HPV type -Globlin
16 18 31 33 35 39 39 39b 45 51 52 56 58 59 68
HPV
16
n1 7344a 50 79 28 26 99 29 128 34 69 36 51 44 41 37 56
n2  7731 43 25 52 29 143 27 169 62 77 40 61 69 56 33 87
n3  8354 62 40 38 34 127 46 173 52 69 42 47 84 66 41 79
HPV
18
n1  29 11,685 39 36 65 113 41 154 58 87 44 51 107 62 46 97
n2  52 13,202 64 52 58 148 35 183 59 98 65 70 88 71 40 106
n3  20 10,953 51 32 49 113 19 132 52 77 43 51 70 53 34 69
HPV
31
n1  37 55 10,814 45 46 107 36 143 55 86 49 51 65 62 33 69
n2  29 51 11,271 48 43 129 41 170 66 72 50 42 87 86 30 90
n3  26 67 10,889 53 56 151 21 172 58 72 41 53 88 73 31 94
HPV
33
n1  48 39 50 9353 49 132 29 161 60 68 56 41 108 83 26 86
n2  37 32 39 8961 51 128 38 166 48 66 31 47 95 54 26 72
n3  35 70 56 9003 48 117 21 138 43 58 38 50 120 64 25 94
HPV
35
n1  53 40 69 56 6394 140 38 178 52 78 57 23 85 72 38 86
n2  36 60 55 66 6053 136 42 178 63 87 59 63 69 74 49 105
n3  28 47 43 54 6101 134 49 183 59 77 47 48 61 67 26 90
HPV
39
n1  38 57 52 54 37 5259 2448 7706 87 72 49 48 59 57 36 75
n2  60 60 42 35 32 5269 2281 7550 70 60 44 53 84 47 28 104
n3  55 70 43 45 55 5045 2467 7511 59 80 53 53 69 72 15 78
HPV
45
n1  53 50 64 60 42 145 45 190 8185 66 57 45 90 64 29 107
n2  26 58 46 47 34 130 41 171 7763 61 57 40 64 55 33 92
n3  51 47 55 53 46 157 31 188 7519 50 44 51 87 75 30 87
HPV
51
n1  31 77 65 57 30 132 44 176 42 8552 57 58 60 93 24 88
n2  53 57 66 66 40 152 35 187 66 9101 49 60 69 79 39 95
n3  27 59 50 60 44 145 46 191 76 9504 41 59 91 80 54 98
HPV
52
n1  42 59 58 45 41 165 33 198 66 75 5914 47 75 73 19 85
n2  34 51 57 60 42 140 39 179 74 72 6165 55 65 70 33 92
n3  58 74 47 55 41 148 47 195 67 86 6031 57 79 72 45 123
HPV
56
n1  52 60 64 57 29 192 39 231 68 72 50 9005 64 49 49 83
n2  41 57 68 53 35 142 34 176 87 81 57 8627 75 72 39 85
n3  45 50 59 35 44 124 44 168 34 80 29 7830 62 61 27 83
HPV
58
n1  40 50 60 78 41 142 32 174 81 91 50 60 9647 76 15 80
n2  26 44 46 62 29 133 26 159 96 71 58 54 10,050 56 22 96
n3  27 57 51 65 21 133 18 151 104 95 33 52 10,080 70 38 97
HPV
59
n1  41 35 52 44 31 119 31 150 61 69 54 44 77 9644 30 82
n2  50 56 63 47 50 149 27 176 44 88 34 55 76 10,072 31 72
n3  49 56 63 55 52 147 33 180 68 88 60 45 104 10,364 39 60
HPV
68
n1  46 44 54 42 42 144 42 186 74 81 56 67 83 87 7951 103
n2  24 56 58 43 52 160 27 187 58 86 41 59 79 60 7457 100
n3  38 47 63 32 43 156 49 205 66 59 62 82 70 56 7635 101
-
Globlin
n1  55 77 79 78 74 196 65 261 84 96 76 68 100 103 40 3855
n2  39 57 62 68 55 157 49 206 64 61 57 66 87 78 47 2798
n3  40 65 56 53 57 166 40 206 57 69 59 58 80 76 42 2767
a Speciﬁc signal (bold) is given as MIF.
b Total value of MFI  with two  types of HPV 39-speciﬁc probes.
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Table  3
Detection limit analysis for each HPV type.
Cut-off value Copy number of plasmids per test
62.5 copies 125 copies 250 copies 500 copies 1000 copies
HPV 16 1000 MFI  2245.3 3183.4 4677.3 4882.5 7687.5
CV% 22.1% 29.3% 10.0% 14.4% 6.0%
HPV  18 1000 MFI  4781.9 8815.3 10,084.5 10,776.3 10,333.3
CV% 46.2% 4.1% 5.9% 6.3% 10.3%
HPV  31 1000 MFI  2830.3 3410.3 4859.3 5382.4 8191
CV% 10.1% 18.7% 12.0% 10.2% 8.4%
HPV  33 1000 MFI  4941.8 6957.8 7736.7 8757.5 9939.5
CV% 21.5% 16.7% 3.7% 5.4% 3.5%
HPV  35 1000 MFI  6828.4 8324.7 9806.3 9895.8 10,861.2
CV% 17.4% 14.8% 2.8% 6.6% 5.7%
HPV  39 2000 MFI  4380.3 4414.8 5953 6213.3 7140.6
CV% 12.6% 14.5% 6.4% 8.3% 10.3%
HPV  45 1000 MFI  4338.8 6245.7 6945.8 7884.3 9036.2
CV% 13.8% 6.8% 5.9% 4.0% 2.6%
HPV  51 1000 MFI  2215.3 2752.3 4123 5609.3 8500.3
CV% 36.3% 33.0% 10.0% 8.6% 14.5%
HPV  52 1000 MFI  6255.3 8131.3 10,753.9 11,299.7 15,786.3
CV% 26.9% 16.6% 10.9% 5.9% 3.5%
HPV  56 1000 MFI  4535.8 4731.9 6694.2 7105 9148.1
CV% 14.7% 10.6% 3.5% 5.3% 2.1%
HPV  58 1000 MFI  2348.3 2282 4655.7 4314.5 8778.8
CV% 20.0% 11.2% 16.3% 8.9% 2.9%
HPV  59 1000 MFI  7073.9 6941.4 7930.1 8668.4 10,321.9
CV% 11.8% 6.9% 8.3% 3.7% 2.0%
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9 bead. Consequently, to exceed the maximum sample value of 10
tandard deviations above the mean of the negative sample value
nd to fall below the minimum sample value of 3 standard devia-
ions below the mean of the positive sample value, the provisional
ut-off value of HPV-DNA detection beads was set at 2000 for the
PV 39 bead and 1000 for the other HPV-type beads. The analytical
ensitivity of the multiplex HPV primers was determined for all HPV
ypes included in the assay, using 2-fold dilution series of plasmids
ontaining control plasmid DNA. Duplicate samples were assayed
hrice for each HPV type. DNA from all HPV types was  detected in
ontrol plasmid DNA samples at 125, 250, 500, and 1000 copies/test
Table 3).
.2. Mixed control plasmid sample study
To examine the performance of the assay in the detection of
ultiple HPV-type infections, HPV 16 plasmid DNA was mixed
ith other HPV-type plasmid DNAs at ratios ranging from 1:1 to
:10,000. HPV 16 plasmid could not be detected in samples at a
oncentration of 250 copies/test, when other HPV-type plasmids
ere mixed at concentrations of more than 250 × 103 copies/test.
n contrast, HPV 16 plasmid samples at concentrations of 250 × 104
opies/test could be detected without being inﬂuenced by the con-
entration level of the other HPV-type plasmids (Table 4).
.3. Cross-reactivity study
To assess potential cross-reactivity with other bacteria and
iruses, organism genomes were added to a -globin control
lasmid DNA sample. The microbial strains used were herpes
implex virus type 1, herpes simplex virus type 2, Epstein Barr
irus, adenovirus type 2, cytomegalovirus, Staphylococcus aureus,1604.5 4903.1 5133.1 5239.2
45.6% 4.3% 8.3% 14.3%
Staphylococcus epidermidis, Neisseria lactamica, Escherichia coli, Pro-
teus vulgaris, Klebsiella pneumonia,  Enterobacter cloacae IFO3320,
Haemophilus ducreyi, Lactobacillus gasseri,  Fusobacterium nuclea-
tum, Chlamydia trachomatis, Candida albicans, Mycoplasma homi-
nis,  Mycoplasma hyorhinis, Ureaplasma urealyticum, Trichomonas
vaginalis, Porphyromonas asaccharolytica, Gardnerella vaginalis, Tre-
ponema vincentii, Acinetobacter genomospecies,  Mobiluncus curtisii,
and Clostridium sticklandii.  Puriﬁed viral DNA was tested at 1 × 105
copies/test, and bacterial DNA was added at 1 × 105 cfu/ml. Only -
globin was detected in all samples; therefore, the presence of other
organisms did not affect the detection of HPV DNA in this assay.
3.4. Genotypic speciﬁcity of the PCR products
To conﬁrm that the PCR products were not non-speciﬁc, cloning
and sequencing were performed. All 52 samples showed 99% or
100% identities on BLAST [accession numbers: type 18 (U89349),
type 31 (U37410 and J04353), type 33 (U45897), type 35 (X74477),
type 39 (U45905), type 45 (U45913), type 51 (CQ4877141), type
52 (HQ537743), type 56 (X74483), type 58 (U45929), type 59
(X77858), and type 68 (U45934)], conﬁrming that the assay can
be used for precise HPV genotyping (data not shown).
3.5. Clinical sample analysis
A total of 356 clinical samples were tested using the HPV
genotyping kit. HPV-DNAs were detected in 162 (45.5%) samples,
including 110 (67.9%) with single infection and 52 (32.1%) with
multiple infections, of which 41 (78.8%) were double infections, 7
(13.5%) were triple infections, 3 (5.8%) were quadruple infections,
and 1 (1.9%) was  a quintuple infection. The type distribution of the
13 high-risk HPVs was  as follows: 28.4% HPV 16, 11.7% HPV 18, 6.8%
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Table 4
Mixed control plasmid sample study for detecting HPV 16 plasmid.
HPV type Median ﬂuorescence intensity
Plasmid mixing ratio (HPV 16: other 12 types of HPV)
1:1a 1:100 1:1000 1:10,000 10,000:1 10,000:100 10,000:1000 10,000:10,000
HPV 16 8610 1484 429 232 8908 8490 7315 1620
HPV  18 8360 6095 7826 10,689 9719 11,150 7669 1973
HPV  31 7196 4314 5381 7751 5655 6767 5283 1207
HPV  33 9533 4996 7425 10,709 8770 11,169 8915 1404
HPV  35 9027 2133 2749 3625 8702 5564 3275 497
HPV  39 3484 2455 3403 5267 3318 4720 3706 782
HPV  39 2968 1200 1613 1988 2620 2360 1933 271
HPV  39 6452 3655 5016 7255 5938 7080 5639 1053
HPV  45 6505 4122 5753 7845 6021 8018 5613 1236
HPV  51 7940 3914 7158 9441 6733 8866 6647 1528
HPV  52 10,675 4979 6120 72,526 10,990 10,754 8017 911
HPV  56 7663 4858 5607 8707 7246 8085 5343 1268
HPV  58 3609 2871 5977 8427 1953 5675 4883 1402
HPV  59 8000 4364 7276 9931 7737 8523 7367 2169
HPV  68 8444 5909 5834 8904 7096 8337 6146 1482
-Globin 3233 948 1433 871 3488 2684 1339 111
a 250 copies of HPV 16: 250 copies of each 12 HPV type (total 3000 copies of HPVs).
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aPV 31, 3.1% HPV 33, 3.7% HPV 35, 9.3% HPV 39, 1.9% HPV 45, 8.6%
PV 51, 37.0% HPV 52, 9.3% HPV 56, 16.7% HPV 58, 3.7% HPV 59,
nd 1.9% HPV 68.
.6. Sample stability in liquid-based cytology media
The changes in MFI  over time were measured in 3 types of liquid-
ased cytology media, with a cut-off value of 1000. DNA of HPV
6, HPV 18, and -globin contained in HeLa or SiHa cells could be
etected in Tacas and Thinprep samples stored at 4 ◦C or 30 ◦C for
 weeks or less. In contrast, only HPV 18 was detected in Surepath
amples stored at 4 ◦C or 30 ◦C for 4 weeks. HPV 16 could not be
etected in Surepath samples stored at 4 ◦C for 4 weeks or 30 ◦C
or 2 weeks. Furthermore, -globin was not detected in Surepath
amples stored at 4 ◦C or 30 ◦C for 1 week (Table 5).
. Discussion
To assess the performance of the Mebgen HPV assay, recom-
inant plasmid DNA was used as a reference standard. In the
nvestigation of the accuracy of the assay, MFI  of beads was  con-
rmed in triplicate measurements, and MFI  of type-speciﬁc beads
aried as much as 10- to 100-fold among the other beads. Therefore,
he assay was considered to offer accurate type-speciﬁc detection.
sing a cut-off value of 1000 for MFI  (2000 for HPV 39), each DNA,
xpect HPV 68 DNA, was detected at 62.5 copies/test, and all types
ere detected at 125–1000 copies/test. Therefore, the detection
imit of the assay was determined to be 125 copies/test, and 250
opies/test, provided enough ﬂuorescence intensity to serve as the
inimum detection sensitivity. In the examination of mixed HPV-
ype plasmids for multiple HPV-type infections, HPV 16 could not
e detected in samples that included the minimum detection sen-
itivity concentration when DNA of other HPV types was added at
oncentrations greater than 250 × 103 copies/test. The reason for
his is unknown, but competition for reagents can result in a loss
f sensitivity and the detection of viral types present at lower copy
umbers (Klug et al., 2008) and may  lead even to false-negative
esults. The cloning and sequencing method, which is considered
o obtain the most reliable results, conﬁrmed the validity of the
enotypic speciﬁcity of the ampliﬁed PCR products and conﬁrmed
he reliability of a positive result in this assay. The assay was tested
lso using plasmid control samples along with 27 other types ofmicrobial DNA. There was  no cross-reaction, demonstrating that
the presence of other DNA mixed with HPV DNA in endocervical
curettage specimens did not affect the performance of the assay.
The results of the sample stability test showed that the assay
can be used successfully with the DNA of cultured cells extracted
from Thinprep or Tacas samples stored at 4 ◦C or 30 ◦C for up to 4
weeks. However, Surepath samples should be tested within 1 week
of collection because the ﬁndings suggested that nucleic acid degra-
dation occurred during storage in the medium. Surepath medium
is thought to be more challenging, primarily due to the formalde-
hyde crosslinking of proteins and nucleic acids (Moelans et al.,
2011; Naryshkin and Austin, 2012). HeLa and SiHa cell lines contain
10–50 and 1–2 copies of HPV 18 and HPV 16 DNA/cell, respectively
(Mincheva et al., 1987). According to the DNA concentration of the
sample and the minimum detection sensitivity of the assay, the
amount of detectable DNA decreased by 1/1000–1/10,000 over 4
weeks of storage. Further investigation is required to determine
the appropriate long-term storage conditions for each liquid-based
cytology media.
The 356 clinical samples used in this study were obtained
from patients with persistently abnormal smears diagnosed at
mass public health screenings for cervical cancer; therefore, a
high positive rate (45.5%) of HPV was  observed. However, many
other researchers have reported previously the same genotype
distribution found in this study. Consequently, this distribution
is considered to be characteristic of the HPV-type distribution
in Japan, with HPV 16 detected at a moderately low frequency
and HPV 52 detected at a high frequency compared with the dis-
tributions in European countries (Miura et al., 2006). Additional
statistical studies using new genotyping methods optimized for
mass screening are needed to develop a more effective vaccine that
matches the type distribution of the geographical region.
Currently, there are several commercially available HPV tests,
but all have some limitations. HC2 cannot detect all genotypes
of HPV, and as established previously, its detection limit is 5000
copies of HPV per assay (Lorincz, 1996). In addition, HC2 lacks
internal standards to assess sample quality (Stoler et al., 2007).
The Linear arrayTM HPV genotyping test/line-blot assay using a
manual technique (Roche Diagnostics Gmbh, Mannheim, Germany)
allows the detection of multiple infections and is very sensitive
and well validated (Giuliani et al., 2006). However, it provides
only semi-quantitative results as a visual read-out, which creates
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Table  5
Change over time of median ﬂuorescence intensity in each liquid-based cytology medium (cell concentration: 105 cell/ml).
Week n Stored at 4 ◦C Stored at 30 ◦C Stored at 4 ◦C Stored at 30 ◦C
Thinprep Surepath Tacas Thinprep Surepath Tacas Thinprep Surepath Tacas Thinprep Surepath Tacas
HPV 16 from SiHa cells -Globin from SiHa cells
0 1  8869 9270 8761 8761 8761 8761 3133 3097 3144 3144 3144 3144
2  8934 8980 8748 8748 8748 8748 3316 3121 3139 3139 3139 3139
1 1  8810 2640 8392 8804 2584 8439 3387 95 3160 3410 198 2996
2  9181 3558 9224 9144 3730 9229 3496 95 3527 3755 201 2860
2 1  9800 2927 9638 8883 2745 9991 3777 105 3805 3452 86 2737
2  9538 3239 9153 9989 893 9966 3723 102 3668 3919 163 2891
3 1  9579 2591 8200 9872 61 7384 3894 177 3298 3856 117 1785
2  10,333 2603 7263 10,089 68 6796 4039 132 2706 3892 116 1519
4 1  7435 57 6338 6896 30 8078 2432 81 2322 2699 79 1539
2  6698 1744 7743 7504 916 7809 2439 82 2936 2810 114 1489
HPV  18 from HeLa cells -Globin from HeLa cells
0 1  11,772 11,079 10,796 10,796 10,796 10,796 2697 2361 2546 2546 2546 2546
2  11,985 11,337 12,505 12,505 12,505 12,505 2670 2416 2703 2703 2703 2703
1 1  11,618 11,254 12,490 12,335 11,042 12,425 2938 171 3075 3214 166 2892
2  12,546 11,507 13,265 12,566 10,651 12,925 3329 204 3089 1682 129 2858
2 1  12,725 11,683 12,893 13,331 11,427 14,420 3438 150 3252 3367 108 3007
2  13,154 11,876 13,254 13,605 10,085 14,383 3481 158 3547 3278 134 2901
3 1  13,278 11,869 14,647 13,699 10,546 12,436 3555 105 3360 3188 85 2394
2  13,758 11,779 13,718 13,100 9788 14,480 3702 119 2992 2950 77 2501
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i4 1  10,096 8644 9849 10,841 8967 
2  9595 9083 9428 10,585 7821 
roblems with reproducibility and increase the risk of data entry
rrors (Schmitt et al., 2006). The polymerase chain reaction method
sing MY09/MY11 and/or GP5+/GP6+ primers has been used widely
n the past decade (Castle et al., 2002; Fuessel Haws et al., 2004).
hese consensus primers are able to detect a broad spectrum of HPV
ypes, but because of biased ampliﬁcation, they are not suitable for
enotyping in samples containing multiple HPV types (Mori et al.,
011). The AmplicorTM HPV test (Roche Diagnostics Gmbh) is an
nzyme-linked immunosorbent assay that involves a manual tech-
ique. This test is useful for small laboratories, but it is difﬁcult to
pply in mass screening. Recently, a number of new genotyping
its for dedicated measuring instruments have been commercial-
zed [e.g., the CobasTM HPV test (Roche Diagnostics Gmbh), the
ervistaTM HPV HR test (Hologic), and the Abbott Realtime high
isk HPV test (Abbott Laboratories, IL, USA), all of which use real-
ime PCR assay, and the ClinichipTM HPV (Sekisui medical, Tokyo,
apan), which uses an automated DNA chip system)]. Further, com-
arative testing is necessary to assess the relative advantages of
hese systems.
The Mebgen HPV assay uses the Luminex system to detect
peciﬁc PCR products in a 96-well format. As a result of the advan-
ages of the high-throughput screening method, this system has
ained already a solid reputation in various ﬁelds of genotyp-
ng (e.g., inﬂammatory cytokines, bacterial pathogens, and single
ucleotide polymorphisms) (Armstrong et al., 2000; Dunbar et al.,
003; Skogstrand et al., 2005; Ye et al., 2001). In addition to the use
f the reliable Luminex system, this HPV genotyping kit uses dUTP
n place of dTTP in the dNTP mix, and UDG enzyme is added to the
CR master mix. Because UDG does not react with dUTP and is inac-
ivated also by heat denaturation before the actual PCR, carry-over
ontamination of PCRs can be controlled effectively if the contam-
nants contain uracil in place of thymine (Longo et al., 1990). For
PV genotyping, an appropriate assay should be selected on the
asis of the speciﬁc purpose and aims of each laboratory. The new
ebgen HPV genotyping kit offers another valuable option for use
n the future.,457 2694 183 2321 2674 86 2157
,667 2436 95 2135 2387 62 1792
5. Conclusion
The present ﬁndings suggest that the Mebgen HPV kit can be
potentially used for clinical applications and large-scale epidemio-
logical and vaccination studies. Further studies with larger sample
sizes and a comparative study with another assay are warranted.
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